Guillain-Barre Syndrome
Recent clinical, regulatory, research and industry developments relating to this disease.
Long-term neurologic outcomes of COVID-19.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q4 2026.
Clinical MilestonesViewHide
- 2026-05-28ClinicalAn Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (GBS) (FORWARD Study)Results expected Q4 2026
- 2026-02-20ClinicalPhase 2, Randomized, Patient- and Rater-blinded Single-site Trial Evaluating Safety and Efficacy of Efgartigimod in Patients With Guillain-Barré Syndrome.Withdrawn
- 2025-09-08ClinicalA Phase 3, Prospective, Multicenter, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Eculizumab in Patients With Guillain-Barré Syndrome (GBS)Results posted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes7
- COVID-192
- Angiotensin-Converting Enzyme 21
- Autoantibodies1
- Brain Diseases1
- Guillain-Barre Syndrome1
- Nervous System Diseases1
- SARS-CoV-21
Leading journals3
- Frontiers in immunology1
- Nature medicine1
- Viruses1
Leading researchers8
- Al-Aly Z1
- Alzahrani KJ1
- Azevedo V1
- Barh D1
- Bellucci M1
- Benedetti L1
- Beronio A1
- Bozzano FM1
Affiliations (unnormalised)6
- Centre for Genomics and Applied Gene Technology1
- Clinical Epidemiology Center1
- College for Public Health and Social Justice1
- Department of Clinical Laboratories Sciences1
- Institute for Public Health1
- Instituto de Ciências Biológicas1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.